DOMAIN Therapeutics

Committed to improve patients’ life and to support physicians by delivering innovative immunotherapies to fight cancer

Launch date

2001

Employees

Ownership

venture capital, accelerator

Firm valuation

Illkirch Grand Est (HQ)

http://domaintherapeutics.com

https://twitter.com/domaintherapeut https://www.linkedin.com/company/domain-therapeutics/

Deals in current and previous year:

Revenues, earnings & profits over time

EUR	2016	2017	2018	2019	2020	2021	2022E
Revenues	5m	5m	8m	5m	9m	-	-
% growth	150 %	-	60 %	(38 %)	80 %	-	-
EBITDA	<1m	<1m	<1m	(5m)	(4m)	-	-
% EBITDA margin	10 %	(4 %)	(1 %)	(100 %)	(44 %)	-	-

Source: Company fillings or news article

Date	Investors	Amount	Round
-	Cap Innov'Est Auriga Partners (Paris) SEMIA Kurma Partners	N/A	- Not yet verified
Feb 2002	Sofinnova Partners Auriga Partners	€3m	Series A
May 2004	Bpifrance	€16m	Series B
Oct 2006	Bpifrance	€8.2m	Series C
Dec 2008	N/A	€2.1m	Series D
Jul 2012	Seventure Partners Auriga Partners	€2m	Early VC
Apr 2014	N/A	$230k	Grant
May 2019*	Seventure Partners	€3.5m	Late VC
Jan 2020*	N/A	€6m	Debt
May 2022*	Turenne Capital Seventure Partners Omnes Capital Schroders Theodorus CTI Life Sciences Panacea Venture AdMare BioInnovations Viva BioInnovator 3B Future Health Fund	$42m	Series A
Total Funding		$80.5m

Tech stackLearn more about the technologies and tools that this company uses.

Prestwick Chemical Inc.

ACQUISITION by DOMAIN Therapeutics Mar 2020

Ermium Therapeutics

ACQUISITION by DOMAIN Therapeutics Mar 2020